34 ms·
> cerebrovascular disease, by interacting with FMNL2, reduces the clearance of amyloid in the brain. Hopefully, this sets the stage for a targeted therapy whic
by phnofive 4y ago
> cerebrovascular disease, by interacting with FMNL2, reduces the clearance of amyloid in the brain.
Hopefully, this sets the stage for a targeted therapy which could finally test the amyloid beta theory:
"When drugs that have been shown to reduce amyloid-β are given to people who are expected to develop Alzheimer’s disease and they still don’t work, says Murphy, “that would absolutely convince me we’ve been misled and it has to be wrong”."
(From https://www.nature.com/articles/d41586-018-05719-4 https://www.nature.com/articles/d41586-018-05719-4 )
- JamesBarney 4y agoWe have drugs that remove amyloid-B, they didn't have any effect in clinical trials. (Despite one passing FDA approval) The problem is it was given to people who already had Alzheimer's. And I doubt they'll ever get permission from an IRB to run the study on a patient who are just expected to maybe develop Alzheimer's.
- novok 4y agoI think it's more of an amyloid-B as scar tissue thing. Whats causing the insult to create scar tissue in the first place, and if the body didn't make amyloid-B, what worse thing would happen?